These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19401550)

  • 41. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
    Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
    Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
    Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
    Di Leo A; Isola J
    Clin Breast Cancer; 2003 Aug; 4(3):179-86. PubMed ID: 14499010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    Nielsen KV; Brünner N
    J Natl Cancer Inst; 2011 Feb; 103(4):352-3. PubMed ID: 21217082
    [No Abstract]   [Full Text] [Related]  

  • 46. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anthracyclines and the tailoring of treatment for early breast cancer.
    Piccart-Gebhart MJ
    N Engl J Med; 2006 May; 354(20):2177-9. PubMed ID: 16707755
    [No Abstract]   [Full Text] [Related]  

  • 49. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer.
    Moelans CB; de Weger RA; van Blokland MT; van der Wall E; van Diest PJ
    Mod Pathol; 2010 Jan; 23(1):62-70. PubMed ID: 19767729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
    Nikolényi A; Uhercsák G; Csenki M; Hamar S; Csörgo E; Tánczos E; Thurzó L; Brodowicz T; Wagnerova M; Kahán Z
    Pathol Oncol Res; 2012 Jan; 18(1):61-8. PubMed ID: 21681601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between immunohistochemical expression of topoisomerase IIalpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer.
    Manna Edel F; Teixeira LC; Alvarenga M
    Tumori; 2006; 92(3):222-9. PubMed ID: 16869240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
    Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL
    Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
    Pritchard KI; Munro A; O'Malley FP; Tu D; Li X; Levine MN; Shepherd L; Chia S; Bartlett JM
    Breast Cancer Res Treat; 2012 Jan; 131(2):541-51. PubMed ID: 22042366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doubling back on centromere 17 in early breast cancer.
    Bedard PL; Desmedt C
    Lancet Oncol; 2010 Mar; 11(3):216-7. PubMed ID: 20202603
    [No Abstract]   [Full Text] [Related]  

  • 57. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas.
    Bofin AM; Ytterhus B; Hagmar BM
    Cytopathology; 2003 Dec; 14(6):314-9. PubMed ID: 14632728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.